Investors have been taken on quite the ride over the past 21 months. They've navigated their way through the quickest decline of at least 30% in the history of the benchmark S&P 500 , and have reveled in what's become the strongest bounce back from a bear-market bottom on record. But in spite of the S&P 500 hitting more than five dozen all-time closing highs in 2021, bargains still abound for opportunistic investors. Even better, with most online brokerages doing away with minimum deposit requirements and trading commissions, any amount of money can be put to work and used to further your trek to financial independence -- even $100. If you have $100 that's ready to be invested in the market, which won't be needed for bills or emergencies, the following three no-brainer stocks would make for perfect buys right now. Image source: Getty Images. Western Digital Investors often think of growth stocks and value stocks as existing in their own realms. In other … [Read more...] about 3 No-Brainer Stocks to Invest $100 In Right Now
Share to Twitter Share to Linkedin Growth equity investments in digital-centric companies have further accelerated during Covid-19, following the brief initial freeze in global M&A and growth financing activity in early 2020. Even when measured against what was then a high-water mark for private markets in the pre-pandemic period , the last two years have been remarkable. The widespread availability of liquidity driven by central banks setting historically low interest rates has pushed even more investor capital into higher-risk and higher-return asset classes like growth equity and venture capital, in a search for higher returns. Only in late 2021 did a tightening of monetary policy re-emerge as an imminent prospect. At the same time, homeworking and lockdowns during the pandemic led to certain digital business models like e-commerce marketplaces and online education platforms experience an upward swing in demand for their services. These in turn have … [Read more...] about Is The Pandemic-Era Surge In Growth Equity Investing Sustainable?
Share to Twitter Share to Linkedin Want half a share of Apple, or bitcoin alongside protective puts? The investing, trading and wealth management firms on Forbes’ Fintech 50 2019 offer more than just the services once exclusive to big banks and traditional financial firms. They’re tapping into markets by merging new tricks with the old. Take, for example, the maturing roboadvisor market as it embraces the human side of advising. Pioneer Betterment added human advisors to its mix in 2017 and last year introduced the ability for investors to tailor their automated portfolio allocations. Further evidence of the hybrid-advisor appeal: Digital wealth management platform Personal Capital returns to the Fintech 50 list after announcing an Atlanta office in September to bulk up its team of more than 200 financial advisors, and its free online financial dashboard now claims almost 2 million users. Meanwhile, the new generation of online brokers, … [Read more...] about The Future Of Investing: Fintech 50 2019
- A + A KUALA LUMPUR (Jan 20): Clean energy specialist Solarvest Holdings Bhd, insurers QBE Insurance (Malaysia) Bhd and Anora Agency Sdn Bhd collaborate to provide solar photovoltaic (PV) investors a solar investment insurance product, namely the SolarPro Line-Stoppage insurance policy. In a joint statement on Thursday (Jan 20), the trio said they signed a tripartite memorandum of understanding (MoU) to enable Solarvest to be able to take up, as well as provide its solar PV investors with an all-new solar investment insurance product. The solar investment insurance product, namely the SolarPro Line-Stoppage insurance policy, is a comprehensive general liability policy with consequential loss underwritten by QBE Malaysia, through Anora. According to the three companies, this insurance product is aimed to offer solar PV investors better coverage to ensure business continuity and peace of mind. Solarvest executive director and chief executive officer (CEO) Davis … [Read more...] about Solarvest, QBE Malaysia, Anora collaborate to offer solar investment insurance product
What happened Today's been a very volatile one for meme token Dogecoin ( CRYPTO:DOGE ) . In Asian trading hours, Dogecoin fell off a cliff, dropping nearly 5% in the span of just more than an hour, around 3 a.m. ET. Since then, this token has recovered most of its losses, currently trading down only 0.4% as of 2:50 p.m. ET. Dogecoin has once again gained speculative momentum over the past week, surging on news that Tesla CEO Elon Musk tweeted, once again, about Dogecoin. This time, the so-called "Dogemaster" would be allowing Dogecoin to be used for Tesla merchandise purchases on the company website. However, since that tweet, Dogecoin has fallen back to roughly the same levels it was trading at pre-tweet. Image source: Getty Images. So what For meme cryptos such as Dogecoin, a surge in news flow, or a lack thereof, can make or break this token's near-term returns. Of late, Dogecoin investors have benefited from (often brief) rallies related to some speculative … [Read more...] about What’s Going On With Dogecoin Today?
For more than a decade, growth stocks have been the talk of Wall Street. Historically low lending rates have rolled out the red carpet for fast-paced companies and allowed them to borrow cheaply in order to hire, acquire, and innovate. But what you might not realize is that value stocks have actually outperformed growth stocks over the very long run. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022. Image source: Getty Images. General Motors The days of General Motors ( NYSE:GM ) being just another stagnant auto stock are gone. The electrification of automobiles has placed a multi-decade growth opportunity on the company's doorstep, and it'll undoubtedly run with it. In June, General Motors announced plans to up its investments in electric vehicles (EVs), autonomous vehicles, and batteries to $35 billion by 2025 . The … [Read more...] about 5 Value Stocks That Can Make You Richer in 2022
Berkshire Hathaway ( NYSE:BRK.A ) ( NYSE:BRK.B ) CEO Warren Buffett is widely considered as one of the greatest investors of all time. One of Buffett's keys to success -- and a core lesson learned from his mentor Benjamin Graham -- has been to invest with a so-called "margin of safety." This concept centers on the idea of buying stocks trading a substantial discount relative to their intrinsic value. While the intrinsic value of a stock means different things to different investors, one of the common themes across the galaxy of definitions for this time-tested investing concept is to focus on companies with strong free cash flows, a solid balance sheet, and a growing dividend program. By taking this approach, investors can essentially ignore the inherent volatility in the market from year to year and simply let the company's strong fundamentals do the heavy lifting, so to speak. Which Berkshire Hathaway holdings -- a.k.a. Warren Buffett stocks -- are the best buys during … [Read more...] about 2 Best Warren Buffett Dividend Stocks to Buy Now
Loading up on growth stocks while they're at bargain prices can lead to some great long-term returns for investors. And with many of these stocks falling in recent weeks, there are plenty of good deals available right now. Among the cheapest stocks to consider include Bristol Myers Squibb ( NYSE:BMY ) and Dell Technologies ( NYSE:DELL ) . Both are trading at low earnings multiples and still possess many growth opportunities, so now could be an optimal time to add these safe investments to your portfolio. Image source: Getty Images. 1. Bristol Myers Squibb Although Bristol Myers pays an incredibly attractive 3.6% dividend yield, which is well above the S&P 500 average of 1.3%, you shouldn't overlook the growth potential here. Acquisitions have helped the company expand its top line (sales of $42.5 billion in 2020 were more than double the $20.8 billion Bristol Myers reported just three years earlier) and its portfolio of drugs. In 2019, Bristol Myers … [Read more...] about 2 Absurdly Cheap Growth Stocks to Buy in December
Get ready for a deluge of important approval decisions. This year, before April showers get a chance to bring any May flowers, the FDA is expected to make a slew of important approval decisions. Cancer patients in the U.S. could get some important new treatment options. Shares of the companies involved could put up big gains if the agency delivers the approval decisions investors are hoping for. Big FDA decisions coming up in the first quarter for Bristol Myers Squibb ( NYSE:BMY ) , Eli Lilly ( NYSE:LLY ) AstraZeneca ( NASDAQ:AZN ) , and Merck ( NYSE:MRK ) could send their share prices soaring. Here's what to look for. Image source: Getty Images. Bristol Myers Squibb: Relatlimab Shares of Bristol Myers Squibb have gained around 17% since hitting a 52-week low in November. An FDA approval for a new type of cancer immunotherapy could push this pharma stock even higher. In September, the FDA began a priority review of Bristol Myers Squibb's … [Read more...] about 3 Big FDA Approvals to Watch For in Q1 2022
There's a common expression in the investing community, which goes as follows: "It's a market of stocks, not a stock market." This essentially means that even with the financial markets at or near all-time highs as they are now, not all stocks have fared well. Pharma stock Amgen ( NASDAQ:AMGN ) is a perfect example. At its current share price of $204, the stock is just a touch above its 52-week low and a whopping 26% below its 52-week high. Let's look at whether you should interpret this recent poor stock performance as a buying opportunity or a sign to steer clear of Amgen. Image source: Getty Images. A solid third-quarter performance Amgen reported $6.7 billion in revenue during the third quarter, which equates to a 4.4% growth rate against the year-ago period. What led to Amgen's respectable performance? Given Amgen's diversified portfolio of more than two dozen drugs, there were quite a few moving parts affecting growth in the quarter. Legacy medications such … [Read more...] about Should You Buy This Giant Biotech Stock?